For Healthcare Professionals

An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis


About the study

Phase 2 study of RPT193 in adults with atopic dermatitis

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Inclusion Criteria:

  1. Clinically confirmed diagnosis of active atopic dermatitis (AD), according to the revised Hanifin and Rajka criteria
  2. 12-month history of AD and had no significant flares in AD for at least 4 weeks before screening
  3. inadequate response to a ≥1 month treatment with topical medications
  4. Atopic dermatitis covering ≥10% of the body surface area
  5. EASI score ≥16
  6. Validated Investigator Global Assessment (VIGA) ≥3
  7. Use of emollient(s) at least 2x daily for 1 week prior to baseline
  8. Negative coronavirus disease (COVID)-19 results at screening


Exclusion Criteria:

  1. Uncontrolled moderate-to-severe asthma
  2. Uncontrolled diabetes
  3. Stage III or IV cardiac failure
  4. Severe renal condition
  5. Major surgery within 8 weeks of screening
  6. Immunodeficiency and/or receipt of immunosuppressive drugs within 4 weeks of baseline
  7. Use of systemic Janus kinase (JAK) inhibitor within 8 weeks of baseline
  8. Received live or live-attenuated vaccine within 4 weeks of baseline
  9. Prior receipt of RPT193
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Atopic Dermatitis

Age (in years)

18 - 75


Phase 2

Participants needed


Est. Completion Date

Sep 30, 2024

Treatment type



RAPT Therapeutics, Inc. identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.